alcon.com (ALC) Company Revenue

Stable demand for ophthalmology consumables has created a reliable revenue foundation for Alcon Inc. The company's sales figures confirm this resilience, where 10.98 determines this parameter level. Technological superiority in surgery has enabled the implementation of premium pricing, while the professionalism of top management has ensured strategic growth and a high market reputation for the business within the medtech sector.

Company Revenue: Alcon (ALC) for 07/04/2022 - 11/13/2026

Analytical breakdowns for Alcon (ALC)

- price and consensus price forecast:

Stock Price Alcon Corp|ALC - Price Target Chart

- market capitalization details:

Market Value Alcon Inc.|ALC - Enterprise Value

- book capitalization information:

Accounting Value per Share Alcon|ALC - Company Book Value|Market-to-Book Ratio alcon.com|ALC - Aggregate Company Assets

- debt and solvency information:

- company profitability and valuation multiples indicators:

ALC - Net Income|Company Profit Forecast Alcon Inc.|ALC - P/E Multiple|Forward P/E Multiple alcon.com|ALC - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alcon Inc.|ALC - Operating profit EBITDA|Net earnings per share for the last 12 months Alcon|ALC - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months alcon.com|ALC - Earnings growth in current year|Expected earnings per share trend next year Alcon Inc.

- sales volume and revenue indicators:

ALC - Revenue and Sales Volume|Projected Sales Volume Alcon Corp|ALC - Price-to-Revenue Ratio|Forward Price to Sales Alcon Inc.

Summary company analysis:Alcon Inc.

Investors view Alcon Inc. (ALC) as a stable asset with high growth potential. This metric captures the actual cash inflow from customers, confirming the real volume of commercial operations. The current value of 10.98 regarding the company's sales revenue allows for an assessment of business resilience against a reduction in scheduled operations. This chart reveals risks of slowing innovation due to regulatory pressure. The shares belong to the defensive class of the healthcare sector.

Analysis of competing companies